ARCHIVES

Phase IIb Trial of CRLX101 Fails Overall Survival Endpoint

This article is from The Cancer Letter archive.

Vol. 36 No. 3 | March 29, 2013

Download PDF Visit The Full Archive

Related Articles

Myriad In Partnership To Market Products.

December 14, 2001

Four UICC Programs Available For International Research

July 10, 1981

In Brief: Wittes To Return To NCI As Chief Of Medicine Branch; Owens Heads Cancer Research Coalition

June 8, 1990

FDA unlikely to pull Iressa from market. Iressa a case study in how not to develop a drug, ODAC member says.

April 1, 2005

Funding Opportunities

September 27, 2002

FDA Purges Quality of Life Claims from Oncology Label for ESAs.

March 16, 2007